Heritability of Polycystic Ovary Syndrome: Role of Antimullerian Hormone, Steroids and Leptin
NCT ID: NCT03483792
Last Updated: 2025-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
58 participants
OBSERVATIONAL
2018-04-20
2022-06-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In women, Anti-Müllerian hormone (AMH) is secreted by granulosa cells located in the ovaries within the follicles. Compared to control women, serum AMH level is higher in PCOS women and could play a role in its pathophysiology. The severity of the PCOS phenotype is correlated with the production of AMH.
It is currently described in the literature that daughters of women with PCOS have a 50% risk of developing PCOS, but no genetic cause of transmission is known. In mice (article in press), pregnant females injected with AMH give birth to offspring with PCOS symptoms. The AMH could thus also play a role in the heritability of PCOS in women. Our team demonstrated that AMH, in its active cleaved form, had a direct central action on the hypothalamus by increasing the pulsatility of GnRH, inducing LH hypersecretion. The hypothesis is that AMH remains higher in pregnant women with PCOS and may affect the fetus by altering fetal and maternal hypothalamic secretions or by modifying placental steroid production.
Leptin has a role in reproduction, through its receptors located at the central (hypothalamus) and peripheral (granulosa cells) levels. In excessively high serum concentration, as observed in obesity, it would lead to a dysregulation of GnRH secretion, an alteration of ovarian steroidogenesis and a dysregulation of folliculogenesis.
Will be compare leptin levels in first trimester patients with and without PCOS to look for possible correlations between AMH and leptin and eliminate possible bias.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PCOS group
Plasma dosage
4 x 7 ml of blood punction at each control visit of the three trimesters of pregnancy
placental biopsy
Immediately following delivery (\<12h postpartum), placental biopsies (Collection of 4 placental fragments)
Control group
Plasma dosage
4 x 7 ml of blood punction at each control visit of the three trimesters of pregnancy
placental biopsy
Immediately following delivery (\<12h postpartum), placental biopsies (Collection of 4 placental fragments)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Plasma dosage
4 x 7 ml of blood punction at each control visit of the three trimesters of pregnancy
placental biopsy
Immediately following delivery (\<12h postpartum), placental biopsies (Collection of 4 placental fragments)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* in the first trimester of mono fetal pregnancy (between 5 and 10 weeks of gestation), obtained spontaneously, after induction of ovulation or Assisted Reproductive Techniques (ART)
* Pregnancy followed at University Hospital of Lille
* PCOS group: defined according to modified Rotterdam criteria (2003 and 2011)
* At least 2 of the following 3 criterion:
* Cycle disorder
* Clinical and / or biological hyperandrogenism
* Ovarian volume \> 10cm³ and/or more than 19 follicles from 2 to 9 mm per ovary
* After exclusion of other causes of cycle disorder or hyperandrogenism
* Control group: patient with severe male and / or tubal infertility, no cycling disorder, normal ovarian reserve (FSH\<10 IU / L, E2\<50 pg / ml, AMH\>7 and \<35 pmol / L and Follicles count between \>5 and \<20 per ovary at day 3 of the cycle).
In the group of female controls, the fertility problem is not related to a female pathology of the hypothalamic-pituitary-ovarian axis (tubal or male infertility). They are women without ovarian personal pathology. The problem of fertility being of other origin.
Exclusion Criteria
* Pregnancy after egg donation
* Long-term drug therapy (excluding routine pregnancy supplementation)
* Previous Diabetes
* Bariatric surgery
* Patients with ovulatory infertility of central or idiopathic origin
* Patients already included in another protocol
18 Years
43 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Lille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sophie Catteau-Jonard, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Lille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Jeanne de Flandres, CHU
Lille, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Peigne M, Simon V, Pigny P, Mimouni NEH, Martin C, Dewailly D, Catteau-Jonard S, Giacobini P. Changes in circulating forms of anti-Muullerian hormone and androgens in women with and without PCOS: a systematic longitudinal study throughout pregnancy. Hum Reprod. 2023 May 2;38(5):938-950. doi: 10.1093/humrep/dead050.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A02628-45
Identifier Type: OTHER
Identifier Source: secondary_id
2017_11
Identifier Type: -
Identifier Source: org_study_id